Year |
Citation |
Score |
2021 |
Ulu A, Velazquez JV, Burr A, Sveiven SN, Yang J, Bravo C, Hammock BD, Nordgren TM. Sex-Specific Differences in Resolution of Airway Inflammation in Transgenic Mice Following Repetitive Agricultural Dust Exposure. Frontiers in Pharmacology. 12: 785193. PMID 35095496 DOI: 10.3389/fphar.2021.785193 |
0.357 |
|
2019 |
Klocke J, Ulu A, Wu K, Rudolph B, Dragun D, Gollasch M, Schunck WH, Hammock BD, Riemekasten G, Enghard P. Prophylactic inhibition of soluble epoxide hydrolase delays onset of nephritis and ameliorates kidney damage in NZB/W F1 mice. Scientific Reports. 9: 8993. PMID 31222024 DOI: 10.1038/S41598-019-45299-5 |
0.451 |
|
2018 |
Lee KSS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, et al. Correction to Optimized Inhibitors of Soluble Epoxide Hydrolase Improve in Vitro Target Residence Time and in Vivo Efficacy. Journal of Medicinal Chemistry. PMID 29701466 DOI: 10.1021/Acs.Jmedchem.8B00582 |
0.597 |
|
2016 |
Ulu A, Inceoglu B, Yang J, Singh V, Vito S, Wulff H, Hammock BD. Inhibition of soluble epoxide hydrolase as a novel approach to high dose diazepam induced hypotension. Journal of Clinical Toxicology. 6. PMID 28255523 DOI: 10.4172/2161-0495.1000300 |
0.406 |
|
2016 |
Kim J, Ulu A, Wan D, Yang J, Hammock BD, Weiss RH. Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy. Molecular Cancer Therapeutics. PMID 26921392 DOI: 10.1158/1535-7163.Mct-15-0847 |
0.472 |
|
2014 |
Terry CM, Carlson ML, He Y, Ulu A, Morisseau C, Blumenthal DK, Hammock BD, Cheung AK. Aberrant soluble epoxide hydrolase and oxylipin levels in a porcine arteriovenous graft stenosis model. Journal of Vascular Research. 51: 269-82. PMID 25196102 DOI: 10.1159/000365251 |
0.463 |
|
2014 |
Lee KS, Liu JY, Wagner KM, Pakhomova S, Dong H, Morisseau C, Fu SH, Yang J, Wang P, Ulu A, Mate CA, Nguyen LV, Hwang SH, Edin ML, Mara AA, et al. Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. Journal of Medicinal Chemistry. 57: 7016-30. PMID 25079952 DOI: 10.1021/Jm500694P |
0.631 |
|
2014 |
Ulu A, Stephen Lee KS, Miyabe C, Yang J, Hammock BG, Dong H, Hammock BD. An omega-3 epoxide of docosahexaenoic acid lowers blood pressure in angiotensin-II-dependent hypertension. Journal of Cardiovascular Pharmacology. 64: 87-99. PMID 24691274 DOI: 10.1097/Fjc.0000000000000094 |
0.466 |
|
2013 |
Ulu A, Harris TR, Morisseau C, Miyabe C, Inoue H, Schuster G, Dong H, Iosif AM, Liu JY, Weiss RH, Chiamvimonvat N, Imig JD, Hammock BD. Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. Journal of Cardiovascular Pharmacology. 62: 285-97. PMID 23676336 DOI: 10.1097/Fjc.0B013E318298E460 |
0.489 |
|
2013 |
Zhang G, Panigrahy D, Mahakian LM, Yang J, Liu JY, Stephen Lee KS, Wettersten HI, Ulu A, Hu X, Tam S, Hwang SH, Ingham ES, Kieran MW, Weiss RH, Ferrara KW, et al. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proceedings of the National Academy of Sciences of the United States of America. 110: 6530-5. PMID 23553837 DOI: 10.1073/Pnas.1304321110 |
0.467 |
|
2013 |
Guedes AG, Morisseau C, Sole A, Soares JH, Ulu A, Dong H, Hammock BD. Use of a soluble epoxide hydrolase inhibitor as an adjunctive analgesic in a horse with laminitis. Veterinary Anaesthesia and Analgesia. 40: 440-8. PMID 23463912 DOI: 10.1111/Vaa.12030 |
0.47 |
|
2012 |
Morisseau C, Schebb NH, Dong H, Ulu A, Aronov PA, Hammock BD. Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic acids. Biochemical and Biophysical Research Communications. 419: 796-800. PMID 22387545 DOI: 10.1016/J.Bbrc.2012.02.108 |
0.477 |
|
2012 |
Ulu A, Appt S, Morisseau C, Hwang SH, Jones PD, Rose TE, Dong H, Lango J, Yang J, Tsai HJ, Miyabe C, Fortenbach C, Adams MR, Hammock BD. Pharmacokinetics and in vivo potency of soluble epoxide hydrolase inhibitors in cynomolgus monkeys. British Journal of Pharmacology. 165: 1401-12. PMID 21880036 DOI: 10.1111/J.1476-5381.2011.01641.X |
0.603 |
|
2011 |
Liu JY, Qiu H, Morisseau C, Hwang SH, Tsai HJ, Ulu A, Chiamvimonvat N, Hammock BD. Inhibition of soluble epoxide hydrolase contributes to the anti-inflammatory effect of antimicrobial triclocarban in a murine model. Toxicology and Applied Pharmacology. 255: 200-6. PMID 21741984 DOI: 10.1016/J.Taap.2011.06.017 |
0.596 |
|
2011 |
Inceoglu B, Wagner K, Schebb NH, Morisseau C, Jinks SL, Ulu A, Hegedus C, Rose T, Brosnan R, Hammock BD. Analgesia mediated by soluble epoxide hydrolase inhibitors is dependent on cAMP. Proceedings of the National Academy of Sciences of the United States of America. 108: 5093-7. PMID 21383170 DOI: 10.1073/Pnas.1101073108 |
0.629 |
|
2011 |
Koeners MP, Wesseling S, Ulu A, Sepúlveda RL, Morisseau C, Braam B, Hammock BD, Joles JA. Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats. American Journal of Physiology. Endocrinology and Metabolism. 300: E691-8. PMID 21266668 DOI: 10.1152/Ajpendo.00710.2010 |
0.422 |
|
2010 |
Wang YX, Ulu A, Zhang LN, Hammock B. Soluble epoxide hydrolase in atherosclerosis. Current Atherosclerosis Reports. 12: 174-83. PMID 20425256 DOI: 10.1007/S11883-010-0108-5 |
0.477 |
|
2010 |
Liu JY, Yang J, Inceoglu B, Qiu H, Ulu A, Hwang SH, Chiamvimonvat N, Hammock BD. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochemical Pharmacology. 79: 880-7. PMID 19896470 DOI: 10.1016/J.Bcp.2009.10.025 |
0.509 |
|
2008 |
Inceoglu B, Jinks SL, Ulu A, Hegedus CM, Georgi K, Schmelzer KR, Wagner K, Jones PD, Morisseau C, Hammock BD. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proceedings of the National Academy of Sciences of the United States of America. 105: 18901-6. PMID 19028872 DOI: 10.1073/Pnas.0809765105 |
0.639 |
|
2008 |
Ulu A, Davis BB, Tsai HJ, Kim IH, Morisseau C, Inceoglu B, Fiehn O, Hammock BD, Weiss RH. Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. Journal of Cardiovascular Pharmacology. 52: 314-23. PMID 18791465 DOI: 10.1097/Fjc.0B013E318185Fa3C |
0.604 |
|
Show low-probability matches. |